208 related articles for article (PubMed ID: 29285650)
21. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
[TBL] [Abstract][Full Text] [Related]
22. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
Endocrine; 2019 Jul; 65(1):110-120. PubMed ID: 31102069
[TBL] [Abstract][Full Text] [Related]
23. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.
Lu R; Yang J; Wei R; Ke J; Tian Q; Yu F; Liu J; Zhang J; Hong T
PLoS One; 2018; 13(6):e0198938. PubMed ID: 29897998
[TBL] [Abstract][Full Text] [Related]
24. Protective effects of gemigliptin against type II collagen degradation in human chondrocytes.
Mohetaer M; Li G; Wang Y; Cao L
Biomed Pharmacother; 2018 Aug; 104():590-594. PubMed ID: 29803171
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
[TBL] [Abstract][Full Text] [Related]
26. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
28. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
[TBL] [Abstract][Full Text] [Related]
29. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
30. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Horm Metab Res; 2013 Jun; 45(6):408-14. PubMed ID: 23386415
[TBL] [Abstract][Full Text] [Related]
32. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
33. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
[TBL] [Abstract][Full Text] [Related]
34. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.
Bikas A; Jensen K; Patel A; Costello J; McDaniel D; Klubo-Gwiezdzinska J; Larin O; Hoperia V; Burman KD; Boyle L; Wartofsky L; Vasko V
Endocr Relat Cancer; 2015 Dec; 22(6):919-32. PubMed ID: 26362676
[TBL] [Abstract][Full Text] [Related]
35. Metformin inhibits endothelial progenitor cell migration by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the AMPK/mTOR/autophagy pathway.
Li WD; Li NP; Song DD; Rong JJ; Qian AM; Li XQ
Int J Mol Med; 2017 May; 39(5):1262-1268. PubMed ID: 28339020
[TBL] [Abstract][Full Text] [Related]
36. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
37. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
He L; Zhang T; Sun W; Qin Y; Wang Z; Dong W; Zhang H
Med Oncol; 2020 Oct; 37(11):97. PubMed ID: 33001278
[TBL] [Abstract][Full Text] [Related]
38. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
[TBL] [Abstract][Full Text] [Related]
39. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
